Shawn Tomasello
Shawn Tomasello's purchase track record
Shawn Tomasello has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/21/2026 | CABA | $50K | +35.5% | +17.5% | +9.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Kalaris Therapeutics Moves in Pre-Market Amid Low RSI. Kalaris Therapeutics was highlighted in a roundup of health care stocks moving in Wednesday's pre-market session. The stock is currently trading near its 52-week low, with the RSI indicating oversold conditions. Analysts maintain a wide range of price targets for the company, reflecting varying views on its future performance.
Transaction History
| CABA | ▲ Buy | Open Market | 22,725 | $50K | 1/21/2026 | View on chart |
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 6/6/2024 | View on chart |
| KLRS | ▲ Buy | Grant | 35,000 | $0 | 5/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Cabaletta Bio Reports Inducement Grants Under Nasdaq Rule
Cabaletta Bio disclosed inducement grants made under Nasdaq Listing Rule 5635(c)(4). This is a standard regulatory filing that provides transparency on equity compensation issued to new employees. The stock is currently trading near its 52-week low, with technical indicators showing moderate selling pressure.
Cabaletta Bio Reports Inducement Grants Under Nasdaq Rule. Cabaletta Bio disclosed inducement grants made under Nasdaq Listing Rule 5635(c)(4). This is a standard regulatory filing that provides transparency on equity compensation issued to new employees. The stock is currently trading near its 52-week low, with technical indicators showing moderate selling pressure.